Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial Meeting Abstract


Authors: Kelsen, D.; Jhawer, M.; Ilson, D.; Tse, A.; Randazzo, J.; Robinson, E.; Capanu, M.; Shah, M. A.
Abstract Title: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial
Meeting Title: 45th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 27
Issue: 15 Suppl.
Meeting Dates: 2009 May 29-Jun 2
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2009-05-20
Start Page: 204s
Language: English
ACCESSION: WOS:000276606603103
PROVIDER: wos
Notes: Meeting Abstract: 4512 -- Source: Wos
MSK Authors
  1. Archie Tse
    34 Tse
  2. Minaxi Jhawer
    10 Jhawer
  3. Marinela Capanu
    206 Capanu
  4. Manish Shah
    174 Shah
  5. David H Ilson
    269 Ilson
  6. David P Kelsen
    332 Kelsen
  7. Jennifer L Russo
    10 Russo